Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Galactosemia cost-effectiveness of therapy

Introduction

Overview

Overview

The cost-effectiveness of the therapy of galactosemia has primarily been studied with respect to the screening program for the disease and the benefits reaped from it.

Cost-Effectiveness of Therapy

Cost-Effectiveness of Therapy

The screening cost of galactosemia is less than the benefits i.e. QALYs achieved through screening, thereby making its implementation cost-effective[1]. Moreover, decreasing the false-positives [2], using healthcare information systems[3] and economical diagnostic techniques, establishing a centralized laboratory [4] and combining with other screening programs [5] will help in further reducing the financial burden. The efficiency of the neonatal screening policy is also inversely related to the prevailing interest rate in the economy[6].

References

References

  1. ↑ Hatam N, Askarian M, Shirvani S, Siavashi E (2017). “Neonatal Screening: Cost-utility Analysis for Galactosemia”. Iran J Public Health. 46 (1): 112–119. PMC 5401919. PMID 28451536.
  2. ↑ Carroll AE, Downs SM (2006). “Comprehensive cost-utility analysis of newborn screening strategies”. Pediatrics. 117 (5 Pt 2): S287–95. doi:10.1542/peds.2005-2633H. PMID 16735255.
  3. ↑ Hsieh SH, Hsieh SL, Chien YH, Weng YC, Hsu KP, Chen CH; et al. (2010). “Newborn screening healthcare information system based on service-oriented architecture”. J Med Syst. 34 (4): 519–30. doi:10.1007/s10916-009-9265-x. PMID 20703906.
  4. ↑ Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Dunø M; et al. (2012). “Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland–experience and development of a routine program for expanded newborn screening”. Mol Genet Metab. 107 (3): 281–93. doi:10.1016/j.ymgme.2012.06.006. PMID 22795865.
  5. ↑ Padilla CD, Lam ST (2008). “Issues on universal screening for galactosemia”. Ann Acad Med Singap. 37 (12 Suppl): 39–3. PMID 19904445.
  6. ↑ Camelo JS, Fernandes MI, Maciel LM, Scrideli CA, Santos JL, Camargo AS; et al. (2009). “Galactosaemia in a Brazilian population: high incidence and cost-benefit analysis”. J Inherit Metab Dis. 32 Suppl 1: S141–9. doi:10.1007/s10545-009-1112-1. PMID 19418240.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]